KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Liabilities (2016 - 2025)

Arbutus Biopharma's Other Non-Current Liabilities history spans 14 years, with the latest figure at $11.1 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 32.6% year-over-year to $11.1 million; the TTM value through Sep 2025 reached $11.1 million, up 32.6%, while the annual FY2024 figure was $10.2 million, 34.54% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $11.1 million at Arbutus Biopharma, up from $3.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $15.4 million in Q1 2022 and bottomed at $3.6 million in Q1 2021.
  • The 5-year median for Other Non-Current Liabilities is $7.6 million (2023), against an average of $7.7 million.
  • The largest annual shift saw Other Non-Current Liabilities plummeted 81.65% in 2021 before it surged 334.29% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $5.3 million in 2021, then surged by 95.64% to $10.4 million in 2022, then fell by 26.68% to $7.6 million in 2023, then surged by 34.54% to $10.2 million in 2024, then increased by 8.09% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Other Non-Current Liabilities are $11.1 million (Q3 2025), $3.9 million (Q2 2025), and $4.4 million (Q1 2025).